Menu
2024 Session

Budget Amendments - SB30 (Floor Approved)

View Budget Item
View Budget Item amendments

Coverage of Long-Acting Injectables or Extended-Release Medications

Item 288 #5s

Item 288 #5s

First Year - FY2025 Second Year - FY2026
Health and Human Resources
Department of Medical Assistance Services FY2025 $177,789 FY2026 $177,906 GF
FY2025 $1,274,312 FY2026 $1,274,094 NGF

Language
Page 319, line 23, strike "$23,331,209,172" and insert "$23,332,661,273".
Page 319, line 23, strike "$24,879,038,632" and insert "$24,880,490,632".

Page 348, after line 43, insert:

"WWWW. Effective July 1, 2024, the Department of Medical Assistance Services shall amend the State Plan for Medical Assistance Services to include a provision for payment of medical assistance, at the prevailing fee schedule, for FDA approved long-acting injectable or extended-release medications administered for a serious mental illness or a substance use disorder in any hospital emergency department or an inpatient setting, including a state hospital or state psychiatric facility."



Explanation

(This amendment provides $177,789 the first year and $177,906 the second year from the general fund and $1.3 million from nongeneral funds in each year to provide for the reimbursement, outside the daily rate, for long-acting injectable (LAI) or extended-release (ER) medications that treat serious mental illness and substance use disorder and which are administered in the hospital emergency department and inpatient settings as well as in state hospitals, including state psychiatric hospitals. LAI or ER medications that treat serious mental illness and substance use disorder, and which are administered in hospital in-patient or emergency department settings, are not currently reimbursed outside the daily rate. While certain forms of long-acting injectables are covered on Virginia’s preferred drug list, the reimbursement is limited to outpatient settings of care. As a result, individuals with serious mental illness or substance use disorders may not have access to LAI medications in a hospital setting, which results in a significant risk to the continuity of care and overall health of these patients, particularly given the complexity of adhering to an oral regiment for many individuals who experience these illnesses.)